Navigation Links
Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
Date:9/29/2008

First complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Sept. 29 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD) announced today that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF). Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD.

"POT-4 has generated encouraging safety and tolerability data in this Phase I study and holds significant promise as a novel agent for treating AMD; a debilitating condition for which there is no cure," said Cedric Francois, President and CEO of Potentia. "As a result of the favorable early data, it was decided to expand the trial to permit further dose escalation, with the goal of prolonging the pharmacological benefit from POT-4. Potentia looks forward to the presentation of the Phase I data at a future medical conference and, with additional information gained from the extension of the study, to the initiation of Phase II trials in the future."

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

Abo
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Potential Early Warning System for Lung Cancer Identified
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Serving a region of ... Rico , Caribbean Imaging and Radiation Therapy (CIRT, ... therapy capabilities with the acquisition of an Elekta Versa HD™ ... Versa HD offers clinicians the versatility to deliver conventional therapies ... while also enabling treatment of highly complex cancers that require ...
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... that Kyle Guse , Chief Financial Officer ... LLP MicroCap Conference on Thursday, May 30, 2013, in ... Hotel. The Company,s presentation is scheduled to ... a live webcast. To access the webcast, go to ...
(Date:5/17/2013)... NATICK, Mass. , May 17, 2013  Boston ... to participate at the annual EuroPCR Scientific Program May ... "We are pleased to present a particularly rich and ... Keith Dawkins , M.D., global chief ... several trials will be presented, including the NG PROMUS ...
Breaking Medicine Technology:Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
(Date:5/19/2013)... 19 (HealthDay News) -- Although spring arrived late this ... allergy season will still be strong, according to a ... Dr. Richard Waguespack, clinical professor in the university,s ... in a robust summer allergy season. However, some simple ... wheezing and coughing, he added. "Tree pollen has ...
(Date:5/19/2013)... 2013 Healthcare leaders will gather at ... the Walt Disney World Swan and Dolphin in Orlando, ... innovation, care delivery and healthcare reform and implementation. , ... healthcare markets, with consolidation, efficiency and reduced ... Todd Ebert, Amerinet president and CEO. “There is a ...
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... 2013 According to a new ... Forecast (2013 – 2018): By Applications (Healthcare (Endoscopy, ... (CCD, CMOS, Contact IS, Infrared, X-Ray) And Geography" ... market was $8.00 billion in 2012 and is ... an estimated CAGR of 3.84% from 2013 to ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob Poulos ... with fat burning diet plans, training workouts, ... Furnace package, people will receive the Fat Burning Furnace ... The Fat Burning Furnace manual includes fat loss knowledge, ... mass. In addition, this book covers step-by-step instructions, techniques ...
Breaking Medicine News(10 mins):Health News:Managing Seasonal Allergies 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2
... Erdogan tried to quell fears of a pandemic by saying ... country // , is now under control. ... monitor it closely," Erdogan newsmen with visiting Japanese Prime Minister ... out of the question," he added. People identified as carriers ...
... Indians (NRI) have been called upon by Oscar Fernandes, ... to take an active part in the AIDS awareness ... the involvement of related agencies and organizations to contribute ... announcement while addressing the Panel Discussion on HIV/AIDS in ...
... flu in the UK is reported to be on the decline. The ... 100,000 people. This figure // has been on the decline since ... for this is reported to be the immunity that the people in ... mutations it goes through every year. ,Most of the ...
... of Bonn in Germany have come up with what could be ... in sunflowers prevents // the AIDS virus from replicating in cell ... to the actual disease. ,The substance called as 'DCQA' ... AIDS drugs. But this is available in very minute quantities and ...
... a controversial procedure used to stitch up the torn hymen ... popularity in the United States // , for different reasons. ... - long considered the only positive proof of virginity - ... American Society of Plastic Surgeons says. ,Gynecologists ...
... to the transport you use. Travelling by taxis results ... least. // ,Research published in the ... College, London, and the Health and Safety Laboratory, Buxton, ... different modes of transport across London. ,Ultra ...
Cached Medicine News:Health News:Turkish PM says bird flu under control 2Health News:Sunflowers Could Hold the Key to New Class of AIDS Drugs 2Health News:A taxi could increase your exposure to pollution 2
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
Single side double clamp knife holder for the Vibratome 8000...
... The Starter Package is ... up your laboratory. The package ... accessory kit, additional mounting blocks, ... head, and a rotating stage ...
... Package is a solid solution ... The package includes the Vibratome ... mounting blocks, v-block adapter, specimen ... rotating stage assembly for ease ...
Medicine Products: